These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 7168636)

  • 21. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasma lipids in diabetes mellitus.
    Khachadurian AK; Uthman SM
    J Med Liban; 1971; 24(2):105-15. PubMed ID: 5115894
    [No Abstract]   [Full Text] [Related]  

  • 23. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
    Uglesić A; Ljachnicky N
    Schweiz Rundsch Med Prax; 1988 Jul; 77(27-28):755-61. PubMed ID: 3041534
    [No Abstract]   [Full Text] [Related]  

  • 24. Metabolism of plasma and biliary lipids in hyperlipoproteinaemia.
    Leijd B
    Acta Med Scand Suppl; 1979; 635():1-32. PubMed ID: 295570
    [No Abstract]   [Full Text] [Related]  

  • 25. [Alterations of lipid metabolism in primary gout and hyperuircemia].
    Mertz DP; Zaar I; Klöpfer-Zaar M; Henninges D; Thieme G; Scheier CA
    Dtsch Med Wochenschr; 1971 Mar; 96(12):488-93. PubMed ID: 5548321
    [No Abstract]   [Full Text] [Related]  

  • 26. Management of hyperlipidemia in diabetes.
    Vinik AI; O'Brian JT; Georges LP; Leichter SB; Janin Y
    Compr Ther; 1995 Oct; 21(10):602-9. PubMed ID: 8565431
    [No Abstract]   [Full Text] [Related]  

  • 27. [Control of the lipid profile in insulin-dependent diabetic children].
    Cerutti F; Sacchetti C; Baratono S; Levis F; Martini A
    Minerva Med; 1978 Jun; 69(28):1909-16. PubMed ID: 566400
    [No Abstract]   [Full Text] [Related]  

  • 28. Serum lipids in an ambulary diabetic clientele. Effect of therapy with Atromidin (clofibrate).
    Bergqvist N
    Acta Med Scand; 1970 Mar; 187(3):213-8. PubMed ID: 5444978
    [No Abstract]   [Full Text] [Related]  

  • 29. [Contrast-unloading week in the complex therapy of patients with metabolic-alimentary obesity and its effect on changes in body weight and lipid metabolism indices].
    Loĭko VI; Baketova NN; Lebedeva EA; Kolmakov VN; Skovorodnikova ES
    Vopr Pitan; 1979; (5):30-3. PubMed ID: 516598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of glucuronyl-glucosamino-glycan sulfate in a group of patients with blood lipid disorders].
    Cossu G
    Clin Ter; 1979 Jan; 88(2):173-81. PubMed ID: 428197
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of tibric acid (CP-18.254) on plasma lipids in patients with primary endogenous hyperlipoproteinemia].
    Lisch HJ; Sailer S; Braunsteiner H
    Arzneimittelforschung; 1977; 27(10):2017-20. PubMed ID: 579116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Plasmatic lipid pattern in the obese: total lipids, triglycerides, phospholipids, alpha and beta lipoproteic cholesterol and single NEFA (C16-C18)].
    Bertolini AM; Santagostino A
    Minerva Med; 1973 Apr; 64(27):1429-37. PubMed ID: 4708214
    [No Abstract]   [Full Text] [Related]  

  • 33. Changes in hyperlipidemia and hyperlipoproteinemia in morbidly obese patients treated by jejunoileal bypass.
    Scott HW; Dean RH; Younger RK; Butts WH
    Surg Gynecol Obstet; 1974 Mar; 138(3):353-8. PubMed ID: 4811320
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypolipidemic activity of 18beta-glycyrrhetinic acid on streptozotocin-induced diabetic rats.
    Kalaiarasi P; Kaviarasan K; Pugalendi KV
    Eur J Pharmacol; 2009 Jun; 612(1-3):93-7. PubMed ID: 19361497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Poseidonol in the treatment of hyperlipidemia in patients with type 2 diabetes mellitus].
    Panchenko VM; Ershov AA; Isaev VA; ZImovchenko GS; Chernova GI
    Klin Med (Mosk); 2001; 79(6):47-9. PubMed ID: 11521381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 37. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cholesterol, triglycerides and nonesterified fatty acids in the plasma of diabetic patients].
    Swynghedauw B
    Diabete; 1968; 16(1):40-4. PubMed ID: 5743941
    [No Abstract]   [Full Text] [Related]  

  • 40. [On the clinical significance of serum lipid and serum lipoprotein examinations].
    Strasser H; Märki HH
    Schweiz Med Wochenschr; 1967 Oct; 97(42):1397-9. PubMed ID: 4969769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.